INDINAVIR (100 MG)F0D3080.971MG/MG(AI)
INDINAVIR (100 MG)F0D3080.971MG/MG(AI) structure
|
Common Name | INDINAVIR (100 MG)F0D3080.971MG/MG(AI) | ||
|---|---|---|---|---|
| CAS Number | 180683-37-8 | Molecular Weight | 631.80500 | |
| Density | N/A | Boiling Point | 877.9ºC at 760 mmHg | |
| Molecular Formula | C36H49N5O5 | Melting Point | 158 °C | |
| MSDS | N/A | Flash Point | 484.7ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | Indinavir monohydrate |
|---|---|
| Synonym | More Synonyms |
| Boiling Point | 877.9ºC at 760 mmHg |
|---|---|
| Melting Point | 158 °C |
| Molecular Formula | C36H49N5O5 |
| Molecular Weight | 631.80500 |
| Flash Point | 484.7ºC |
| Exact Mass | 631.37300 |
| PSA | 134.24000 |
| LogP | 4.35900 |
| Vapour Pressure | 5.56E-33mmHg at 25°C |
| InChIKey | XTYSXGHMTNTKFH-BDEHJDMKSA-N |
| SMILES | CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O.O |
|
Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs.
Biomaterials 37 , 383-94, (2015) With the advent of the Highly Active Antiretroviral Therapy, the morbidity and the mortality associated to HIV have been considerably reduced. However, 35-40 million people bear the infection worldwid... |
|
|
Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
J. Pharmacol. Exp. Ther. 350(3) , 578-88, (2014) The aim of this study was to investigate whether in vivo drug distribution in brain in monkeys can be reconstructed by integrating four factors: protein expression levels of P-glycoprotein (P-gp)/mult... |
|
|
Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Virol. J. 12(1) , 53, (2015) In South Korea, about 20 types of antiretroviral drugs are used in the treatment of patients with human immunodeficiency virus/acquired immune deficiency syndrome. Since 2010, raltegravir, etravirine,... |
| (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide,hydrate |